15P: Updated OS and final QoL and safety results of a randomised, open-label, phase III study comparing nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced NSCLC aged ≥70 years or with an ECOG PS of 2 (GFPC 08–2015 ENERGY)